These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 30188548)

  • 1. Roche splashes $2.4 billion on Foundation Medicine's cancer platform.
    Sheridan C
    Nat Biotechnol; 2018 Sep; 36(9):779-780. PubMed ID: 30188548
    [No Abstract]   [Full Text] [Related]  

  • 2. Roche spends $1 billion on Foundation Medicine's tumor profiling.
    Ratner M
    Nat Biotechnol; 2015 Mar; 33(3):215-6. PubMed ID: 25748890
    [No Abstract]   [Full Text] [Related]  

  • 3. Let's Talk About Financial Toxicities.
    Katz A
    Oncol Nurs Forum; 2018 May; 45(3):281-282. PubMed ID: 29683119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conducting economic evaluation based on basket clinical trial in the area of precision medicine.
    Nosrati M; Nikfar S
    Expert Rev Pharmacoecon Outcomes Res; 2021 Apr; 21(2):169-171. PubMed ID: 33356657
    [No Abstract]   [Full Text] [Related]  

  • 5. UK’s adopts systematic approach to personalised cancer medicine.
    Fricker J
    Mol Oncol; 2011 Jun; 5(3):217-9. PubMed ID: 21774109
    [No Abstract]   [Full Text] [Related]  

  • 6. Personalized cancer medicine--advances and socio-economic challenges.
    Jackson DB; Sood AK
    Nat Rev Clin Oncol; 2011 Oct; 8(12):735-41. PubMed ID: 21989071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Costs Cast Shadow on Optimism about Treatment.
    Manag Care; 2016 Oct; 25(10):29. PubMed ID: 28121542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Retrospective Analysis of Precision Medicine Outcomes in Patients With Advanced Cancer Reveals Improved Progression-Free Survival Without Increased Health Care Costs.
    Haslem DS; Van Norman SB; Fulde G; Knighton AJ; Belnap T; Butler AM; Rhagunath S; Newman D; Gilbert H; Tudor BP; Lin K; Stone GR; Loughmiller DL; Mishra PJ; Srivastava R; Ford JM; Nadauld LD
    J Oncol Pract; 2017 Feb; 13(2):e108-e119. PubMed ID: 27601506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The financial hazard of personalized medicine and supportive care.
    Carrera PM; Olver I
    Support Care Cancer; 2015 Dec; 23(12):3399-401. PubMed ID: 26306523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cost of getting personal.
    Nat Med; 2019 Dec; 25(12):1797. PubMed ID: 31806890
    [No Abstract]   [Full Text] [Related]  

  • 11. Strata rolls out drug-matching service, offers free tumor profiling.
    Ratner M
    Nat Biotechnol; 2016 Sep; 34(9):895-6. PubMed ID: 27606443
    [No Abstract]   [Full Text] [Related]  

  • 12. Industry panel discusses status of personalized medicine.
    Thompson CA
    Am J Health Syst Pharm; 2012 Mar; 69(5):366. PubMed ID: 22345411
    [No Abstract]   [Full Text] [Related]  

  • 13. Balancing the Economics and Ethics of Personalised Oncology.
    Flaum N; Hall P; McCabe C
    Trends Cancer; 2018 Sep; 4(9):608-615. PubMed ID: 30149879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Market watch: Where is personalized medicine in industry heading?
    Milne CP; Cohen JP; Chakravarthy R
    Nat Rev Drug Discov; 2015 Dec; 14(12):812-3. PubMed ID: 26471367
    [No Abstract]   [Full Text] [Related]  

  • 15. Limits to Personalized Cancer Medicine.
    Tannock IF; Hickman JA
    N Engl J Med; 2016 Sep; 375(13):1289-94. PubMed ID: 27682039
    [No Abstract]   [Full Text] [Related]  

  • 16. The Use of Targeted Therapies for Precision Medicine in Oncology.
    White Al-Habeeb N; Kulasingam V; Diamandis EP; Yousef GM; Tsongalis GJ; Vermeulen L; Zhu Z; Kamel-Reid S
    Clin Chem; 2016 Dec; 62(12):1556-1564. PubMed ID: 27679436
    [No Abstract]   [Full Text] [Related]  

  • 17. [Rising demand for immunodiagnosis].
    Stoschek J
    MMW Fortschr Med; 2015 Aug; 157(14):78. PubMed ID: 26289898
    [No Abstract]   [Full Text] [Related]  

  • 18. Precision Medicine.
    Weil AR
    Health Aff (Millwood); 2018 May; 37(5):687. PubMed ID: 29733714
    [No Abstract]   [Full Text] [Related]  

  • 19. Tales of Personalized Cancer Treatment.
    Demetri G
    Semin Nephrol; 2016 Nov; 36(6):462-467. PubMed ID: 27987546
    [No Abstract]   [Full Text] [Related]  

  • 20. The Impact of Alternative Payment Models on Oncology Innovation and Patient Care.
    Miller AM; Omenn GS; Kean MA
    Clin Cancer Res; 2016 May; 22(10):2335-41. PubMed ID: 27087022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.